Editas Medicine, Inc. (EDIT)
| Market Cap | 4.03B |
| Revenue (ttm) | 81.14M |
| Net Income (ttm) | -166.66M |
| Shares Out | 67.88M |
| EPS (ttm) | -2.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 510,846 |
| Open | 61.31 |
| Previous Close | 62.07 |
| Day's Range | 59.75 - 61.47 |
| 52-Week Range | 27.01 - 99.95 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 53.92 (-12.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is...
Financial Performance
In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 53.92, which is a decrease of -12.05% from the latest price.
News
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
Wood is following an important strategy with gene-editing stocks.
7 Gene Editing Stocks Promising to Change our DNA
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...
Final Trades: Stryker, Editas Medicine, Oracle & more
The "Halftime Report" traders give their top picks to watch for the second half.
3 Red-Hot Healthcare Stocks to Buy in September
These businesses are firing on all cylinders.
Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the I...
Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity
Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and ...
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology
Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were presented at the Cold Spring Harbor Laboratory's G...
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineer...
SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
Will Moderna's Interest Boost Gene Editing Stocks?
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a...
Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
Editas could be an attractive acquisition candidate for the big vaccine maker.
Will The Rally In Editas Stock Continue After A 20% Rise In A Month?
The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and it is a...
Why Editas Medicine Beat the Market on Monday
Another analyst ups his recommendation on the stock.
Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More
With the trading day more than halfway over, the broad markets were fairly mixed. While the Dow Jones industrial average and S&P 500 had pulled back slightly from their all-time highs, they still seem p...
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are C...
Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.
Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More
With the trading day about halfway over, S&P 500, Nasdaq and Dow Jones industrial average were pushing higher for a number of reasons.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine Announces Second Quarter 2021 Results and Business Updates
Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10
Editas (EDIT) to Report Q2 Earnings: What's in the Cards?
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know
In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.